

Applicants' Attorney submits the following amendments to comply with 37 C.F.R.
§1.821:

In the Specification

Please replace the paragraph at page 19, lines 1-13 with the following paragraph:

The invention also relates to isolated nucleic acid molecules comprising SEQ ID NOS: 1-4. SEQ ID NOS: referred to herein are as follows. SEQ ID NO: 1 refers to the nucleic acid sequence of the GK gene having a polymorphic site at nucleotide position 13 of exon 3 as shown in Figure 6. SEQ ID NO: 2 refers to the nucleic acid sequence of the GK gene having a polymorphic site at nucleotide position 17 of intron 8 as shown in Figure 6. SEQ ID NO: 3 refers to the nucleic acid sequence of the GK gene having a polymorphic site at nucleotide position 29 of exon 10 as shown in Figure 6. SEQ ID NO: 4 refers to the nucleic acid sequence of the GK gene having polymorphic site at nucleotide position 22 of intron 12 as shown in Figure 6. In one embodiment, SEQ ID NOS: 1-4 comprise the reference (first) nucleotide at the polymorphic site. In another embodiment, SEQ ID NOS: 1-4 comprise the alternate (second) nucleotide at the polymorphic site. SEQ ID NO: 5 refers to the complete coding nucleic acid sequence of the GK gene, particularly as shown in Figures 7A-7D.

Amendments to the specification are indicated in the attached "Marked Up Version of Amendments" (page i).

REMARKS

This amendment is being made to correct a typographical error that incorrectly described SEQ ID NO.:1 and SEQ ID NO.:3 due to a transposition of the descriptions. Support for this amendment can be found in Figure 6. No new matter has been added.